Literature DB >> 16252133

A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae.

Susan Mabe1, W Scott Champney.   

Abstract

A new streptogramin antibiotic XRP 2868 was compared with quinupristin-dalfopristin for inhibitory activities against antibiotic-resistant Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. In each organism examined, XRP 2868 had an IC(50) that was twofold to fivefold lower than quinupristin-dalfopristin, for inhibition of cell viability, protein synthesis, and ribosomal subunit formation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16252133     DOI： 10.1007/s00284-005-0027-9

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN： 0343-8651            Impact factor:   2.188


  10 in total

Review 1.  Bacterial ribosomal subunit assembly is an antibiotic target.

Authors:  W Scott Champney
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez; Andre Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 4.  New directions in antibacterial research.

Authors:  D T Chu; J J Plattner; L Katz
Journal:  J Med Chem       Date:  1996-09-27       Impact factor: 7.446

5.  Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics.

Authors:  W S Champney; C L Tober
Journal:  Curr Microbiol       Date:  2000-08       Impact factor: 2.188

Review 6.  Linezolid in vitro: mechanism and antibacterial spectrum.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

7.  An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae.

Authors:  W Scott Champney; Nicole Mentens; Kimberly Zurawick
Journal:  Curr Microbiol       Date:  2004-10       Impact factor: 2.188

8.  Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Authors:  Glenn A Pankuch; Linda M Kelly; Gengrong Lin; Andre Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells.

Authors:  W S Champney; R Burdine
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

10.  Preferential inhibition of protein synthesis by ketolide antibiotics in Haemophilus influenzae cells.

Authors:  W Scott Champney; Craig L Tober
Journal:  Curr Microbiol       Date:  2003-02       Impact factor: 2.188
  10 in total
  8 in total

1.  Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae.

Authors:  Glenn A Pankuch; Dianne Hoellman; André Bryskier; John Lowther; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

2.  Crystal structure of the synergistic antibiotic pair, lankamycin and lankacidin, in complex with the large ribosomal subunit.

Authors:  Matthew J Belousoff; Tal Shapira; Anat Bashan; Ella Zimmerman; Haim Rozenberg; Kenji Arakawa; Haruyasu Kinashi; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 3.  Inhibition of bacterial ribosome assembly: a suitable drug target?

Authors:  Bruce A Maguire
Journal:  Microbiol Mol Biol Rev       Date:  2009-03       Impact factor: 11.056

4.  Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells.

Authors:  W Scott Champney; Ward K Rodgers
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

5.  Synergy of streptogramin antibiotics occurs independently of their effects on translation.

Authors:  Jonas Noeske; Jian Huang; Nelson B Olivier; Robert A Giacobbe; Mark Zambrowski; Jamie H D Cate
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 6.  NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.

Authors:  Amani D Politano; Robert G Sawyer
Journal:  Curr Opin Investig Drugs       Date:  2010-02

Review 7.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

Review 8.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.